2021
DOI: 10.12688/wellcomeopenres.16486.1
|View full text |Cite
|
Sign up to set email alerts
|

Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system.

Abstract: The Randomized Embedded Multifactorial Adaptive Platform (REMAP-CAP) adapted for COVID-19) trial is a global adaptive platform trial of hospitalised patients with COVID-19. We describe implementation in three countries under the umbrella of the Wellcome supported Low and Middle Income Country (LMIC) critical  care network: Collaboration for Research, Implementation and Training in Asia (CCA). The collaboration sought to overcome known barriers to multi centre-clinical trials in resource-limited settings. Metho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
25
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
1

Relationship

3
3

Authors

Journals

citations
Cited by 24 publications
(25 citation statements)
references
References 13 publications
0
25
0
Order By: Relevance
“…6 Potential limitations of registry-based trials concern the controlling for confounding and bias. 29 The CCA network is already supporting several of the REMAP-CAP arms trials, 6,30,31 , while also enabling observational and outcome research 22 .…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…6 Potential limitations of registry-based trials concern the controlling for confounding and bias. 29 The CCA network is already supporting several of the REMAP-CAP arms trials, 6,30,31 , while also enabling observational and outcome research 22 .…”
Section: Discussionmentioning
confidence: 99%
“…Regarding trial recruitment, adapted registry platforms promote rapid onboarding, inform site selection and improve patient recruitment, and can facilitate study monitoring through inbuilt data quality and validation processes. 6 Potential limitations of registry-based trials concern the controlling for confounding and bias. 29 The CCA network is already supporting several of the REMAP-CAP arms trials, 6,30,31 , while also enabling observational and outcome research 22 .…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations